Back to Healio Although infrequent, high use of short-acting beta 2 agonists was associated with more severe asthma, according to a study published in The Journal of Allergy and Clinical ...

Background: Current guidelines recommend the use of inhaled corticosteroids (ICSs) added to long-acting β 2-agonists (LABAs) for treatment of symptomatic patients with severe and very severe COPD.

Background: Some studies have suggested that use of long-acting β 2-agonists (LABAs) leads to an increased risk for adverse events in patients with stable COPD. The purpose of this review was to ...

According to the newly published case-control study among people diagnosed with asthma or COPD, the use of inhaled short- or long-acting beta-2 agonists at least three years before Parkinson’s ...

According to the newly published case-control study among people diagnosed with asthma or COPD, the use of inhaled short- or long-acting beta-2 agonists at least three years before Parkinson's ...

This improves airflow and reduces symptoms, such as shortness of breath. Beta-2 agonists come in short-acting varieties to dilate the airway immediately, and long-acting varieties, which maintain ...

According to the newly published case-control study among people diagnosed with asthma or COPD, the use of inhaled short- or long-acting beta-2 agonists at least three years before Parkinson's ...